Stockscreener 앱 받기
24.28
0.71%
0.17
시간 외 거래:
24.22
-0.06
-0.25%
전일 마감가:
$24.11
열려 있는:
$23.83
하루 거래량:
279.49K
Relative Volume:
0.94
시가총액:
$1.09B
수익:
$45.95M
순이익/손실:
$-48.88M
주가수익비율:
-21.82
EPS:
-1.1129
순현금흐름:
$109.67M
1주 성능:
-8.19%
1개월 성능:
-10.34%
6개월 성능:
+54.65%
1년 성능:
+270.69%
1일 변동 폭
$23.35
$24.57
1주일 범위
$23.35
$27.02
52주 변동 폭
$4.66
$32.63
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
24.28 | 1.08B | 45.95M | -48.88M | 109.67M | -1.1129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 개시 | Truist | Buy |
| 2025-11-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | 개시 | H.C. Wainwright | Buy |
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
모두보기
Septerna Inc 주식(SEPN)의 최신 뉴스
Septerna (SEPN) Expected to Announce Earnings on Thursday - MarketBeat
Layoff Watch: Will Septerna Inc outperform the market in YEARTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Septerna (SEPN) Is Down 13.5% After Launching US$150 Million ATM Equity Program and Filing Shelves - simplywall.st
Checkpoint Capital L.P. Trims Stock Position in Septerna, Inc. $SEPN - MarketBeat
Avoro Capital Advisors LLC Grows Stock Holdings in Septerna, Inc. $SEPN - MarketBeat
Septerna (NASDAQ:SEPN) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
HC Wainwright Has Negative Outlook for Septerna Q1 Earnings - MarketBeat
What is HC Wainwright's Forecast for Septerna Q1 Earnings? - MarketBeat
Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL) - The Globe and Mail
Truist Financial Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock - MarketBeat
Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st
Wells Fargo Reaffirms Their Buy Rating on Septerna, Inc. (SEPN) - The Globe and Mail
Truist Lifts Price Target on Septerna to $35 From $34, Keeps Buy Rating - marketscreener.com
Cantor Fitzgerald Maintains Overweight on Septerna, Inc. (SEPN) March 2026 - Meyka
Truist raises Septerna stock price target to $35 on trial progress - Investing.com
Cantor Fitzgerald reiterates Septerna stock rating on platform value By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Septerna stock rating on platform value - Investing.com
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M - AlphaStreet
Septerna beats fourth quarter loss estimates on collaboration revenue By Investing.com - Investing.com India
Septerna beats fourth quarter loss estimates on collaboration revenue - Investing.com
Decoding Septerna Inc (SEPN): A Strategic SWOT Insight - GuruFocus
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24 - marketscreener.com
Biotech firm Septerna beats Q4 revenue expectations, net loss narrows - TradingView
Earnings Summary: Septerna Q4 - Benzinga
Septerna, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
SEPN: Pipeline advances and improved financials set stage for clinical milestones in 2026 - TradingView
Earnings Flash (SEPN) Septerna, Inc. Reports Q4 Revenue $24.1M, vs. FactSet Est of $18.2M - marketscreener.com
SEPN SEC FilingsSepterna, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To Septerna (SEPN) Advancing SEP-631 Into Phase 2b Urticaria Trials - simplywall.st
Can Septerna Inc. stock hit record highs againEarnings Performance Report & Fast Exit Strategy with Risk Control - Naître et grandir
Insider Selling: Septerna (NASDAQ:SEPN) Insider Sells 70,453 Shares of Stock - MarketBeat
Septerna (SEPN) CPO exercises options, then sells 70,453 shares - Stock Titan
Septerna Executive Sells Shares - TradingView
SEPN: SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials - TradingView
SEPN: SEP-631 and SEP-479 advance with strong data, phase 2 and 1 trials planned, and pipeline growth - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN), Payoneer (PAYO) and Porch Group (PRCH) - The Globe and Mail
Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm
A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment - Sahm
Septerna (SEPN) Receives Overweight Rating and Target Price Hike by Wells Fargo | SEPN Stock News - GuruFocus
Wells Fargo & Company Increases Septerna (NASDAQ:SEPN) Price Target to $48.00 - MarketBeat
Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)? - Yahoo Finance
[144] Septerna, Inc. SEC Filing - Stock Titan
Septerna (NASDAQ:SEPN) Price Target Raised to $40.00 at HC Wainwright - MarketBeat
Septerna Advances SEP-631 After Positive Phase 1 Results - TipRanks
SEPN: SEP-631 showed strong Phase 1 efficacy and safety, advancing to Phase 2 for urticaria in 2026 - TradingView
Septerna reports positive Phase 1 SEP-631 data; plans Phase 2b CSU study in 2H 2026 - TradingView
Positive SEP-631 trial data drives Phase 2 plan at Septerna (NASDAQ: SEPN) - Stock Titan
Septerna’s SEP-631 shows positive Phase 1 trial results - Investing.com Australia
Septerna’s SEP-631 shows positive Phase 1 trial results By Investing.com - Investing.com South Africa
Septerna Inc (SEPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):